Lung cancer: Cetuximab, you're fired

Nature Reviews Clinical Oncology

Volumn 11, Issue 1, 2014, Pages 3-

  Villanueva, M Teresa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; PEMETREXED; ANTINEOPLASTIC AGENT;

DRUG RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 84890998967     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.227     Document Type: Note

References (1)

1. Kim, D. S. et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. doi:10.1016/S1470-2045(13)70473-X